Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 48

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 48
---
 Wales on February 11, 1998 with the goal of leveraging the expertise of our management team as well as Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Howard Weiner and Dr. Kevan Herold, and to acquire and exploit certain intellectual property in biotechnology. We subsequently changed our name to Tiziana Life Sciences plc in April 2014 as a result of the acquisition of Tiziana Pharma Limited in April 2014. Our registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda and our telephone number is +44 (0) 20 7495 2379. Our website address is www.tizianalifesciences.com. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website is not a part of this registration statement. Our agent for service of process in the United States is Tiziana Therapeutics, Inc.

<div align='center'>S-4</div>

The Offering

| Common shares offered by us                            |     | Common shares                                                                                                                           
 having an aggregate offering price of up to US$100,000,000.                                                                             |
| Common shares to be outstanding immediately after this 
 offering                                               |     | Up to 180,541,999 shares,                                                                                                               
 assuming the sale of up to 63,694,267 shares hereunder at a price of $1.57 per share, the closing price per share on The Nasdaq Capital 
 Market on March 14, 2025 for aggregate gross proceeds of $100,000,000.  Actual shares issued will vary depending on the                 
 sales price under this offering.                                                                                                        |
| Plan of Distribution                                   |     | “At the market offering” that                                                                                                           
 may be made from time to time on The Nasdaq Capital Market or other existing trading market for our common stock through our sales      
 agent, Jefferies LLC. See “Plan of Distribution” on page S-22 of this prospectus.                                                       |
| Use of Proceeds                                        |     | We intend to use net proceeds                                                                                                           
 from this offering (i) to complete our Phase 2a clinical trial for the intra-nasal delivery of foralumab in patients with non-active    
 secondary progressive multiple sclerosis, (ii) to expedite the clinical development of foralumab in Alzheimer’s disease, (iii)          
 to develop foral